BTIG Research's Rating of Serina Therapeutics on 11/16/2026

On November 16, 2026, BTIG Research updated its outlook on Serina Therapeutics (NYSEAMERICAN:SER) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BTIG Research

DateCompanyAction
11/17/2026
V.F. Corporation stock logo
VFC
V.F.
Set Price Target
11/17/2026
Spire Inc. stock logo
SR
Spire
Reiterated Rating
11/17/2026
Turning Point Brands, Inc. stock logo
TPB
Turning Point Brands
Reiterated Rating
11/17/2026
Ispire Technology Inc. stock logo
ISPR
Ispire Technology
Set Price Target
11/17/2026
Philip Morris International Inc. stock logo
PM
Philip Morris International
Set Price Target
11/17/2026
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Reiterated Rating
More Ratings From BTIG Research